Search results
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
INSIDER via Yahoo News· 7 days agoNew products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. The FDA approved...
What You Should Know Before Taking Popular Weight Loss Drugs Like Ozempic And Wegovy
Forbes· 7 days agoThe drugs work by stimulating the release of insulin from the pancreas which decreases blood sugar...
Some Analysts Do Not Want You To Write Off Madrigal In Favor Of Eli Lilly And Company's GLP-1...
Wccftech· 3 days agoEli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when...
Weight loss: Zepbound effective for obesity-related health conditions
Medical News Today· 6 days agoAnti-obesity medication Zepbound (tirzepatide) delivers significant weight loss even in people with...
Diane Jackson: Medicare should cover anti-obesity medicines
The Lewiston Sun Journal· 17 hours agoRural communities in Maine face significant disparities in accessing essential health care services. Recent findings from the U.S. Department of Agriculture reveal a growing gap in mortality ...
Study finds semaglutide associated with reduction in incidence and recurrence of alcohol-use...
Medical Xpress· 5 days agoTo date, the U.S. Food and Drug Administration (FDA) has approved only three medications to treat...
Drugs like Ozempic, Wegovy may help prevent alcohol use disorder
MedicalNewsToday via AOL· 3 days agoNew research has found that people who take drugs such as Ozempic and Wegovy are more than 50% less...
GLP-1 receptor agonists: Are they friends or foes in colorectal cancer?
MedicalNewsToday via AOL· 4 days agoA new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal...
Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
NBC Dallas Fort Worth· 2 days agoAnat Ashkenazi, Alphabet's incoming CFO, has been running the books at Eli Lilly during a period of historic growth. Eli Lilly has emerged as the most valuable drugmaker in the world on the ...
GLP-1 Coverage Often Denied for Teens With Obesity
Medscape· 7 days agoInsurance companies frequently deny insurance coverage of glucagon-like peptide-1 (GLP-1) receptor agonists for adolescents, according to a new analysis. For those whose GLP-1 prescriptions ...